Humanin vs Klotho
A side-by-side research comparison of Humanin and Klotho across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Humanin | Klotho |
|---|---|---|
| Full name | Humanin (HN) Mitochondrial-Derived Peptide | Klotho Protein |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Research compound (preclinical/early) |
| Mechanism | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. | Exists in membrane-bound and soluble forms. Soluble Klotho acts as a circulating hormone that modulates FGF23 signaling, regulates phosphate/vitamin D balance, suppresses certain growth and oxidative-stress pathways, and supports synaptic and cognitive function. |
| Molecular weight | 2,687 Da | ~130 kDa (full protein; fragments studied) |
| Half-life | 4-6 hours | Not well established for therapeutic forms |
| Bioavailability | Moderate (SubQ) | Injectable in research; large protein with limited oral absorption |
| Typical dose | 1-5 mg | No established human dose |
| Frequency | 3-5x per week | Unknown |
| Route | Subcutaneous | Injection (research) |
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
Klotho reported benefits
- Associated with longevity and slower aging
- Neuroprotection and improved cognition (preclinical)
- Supports kidney and cardiovascular health
- Regulates phosphate and mineral balance
Related comparisons
Research and educational reference only. Not medical advice.